Synonym
N-Desmethyltoremifene; 110503-61-2; N-Demethyltoremifene; 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N-methylethanamine; 2EBS4A61GK
IUPAC/Chemical Name
(Z)-2-(4-(4-chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)-N-methylethan-1-amine
InChi Key
WKJKBQYEFAFHCY-IZHYLOQSSA-N
InChi Code
InChI=1S/C25H26ClNO/c1-27-18-19-28-23-14-12-22(13-15-23)25(21-10-6-3-7-11-21)24(16-17-26)20-8-4-2-5-9-20/h2-15,27H,16-19H2,1H3/b25-24-
SMILES Code
CNCCOC1=CC=C(C=C1)C(=C(\CCCl)C2=CC=CC=C2)\C3=CC=CC=C3
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
391.94
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kim J, Peraire C, Solà J, Johanning KM, Dalton JT, Veverka KA. Drug
interaction potential of toremifene and N-desmethyltoremifene with multiple
cytochrome P450 isoforms. Xenobiotica. 2011 Oct;41(10):851-62. doi:
10.3109/00498254.2011.590546. Epub 2011 Jul 5. PMID: 21726172.
2: Lara PN Jr, Gandara DR, Wurz GT, Lau D, Uhrich M, Turrell C, Raschko J,
Edelman MJ, Synold T, Doroshow J, Muggia F, Perez EA, DeGregorio M. High-dose
toremifene as a cisplatin modulator in metastatic non-small cell lung cancer:
targeted plasma levels are achievable clinically. Cancer Chemother Pharmacol.
1998;42(6):504-8. doi: 10.1007/s002800050852. PMID: 9788578.
3: Wiebe VJ, Benz CC, Shemano I, Cadman TB, DeGregorio MW. Pharmacokinetics of
toremifene and its metabolites in patients with advanced breast cancer. Cancer
Chemother Pharmacol. 1990;25(4):247-51. doi: 10.1007/BF00684880. PMID: 2136809.
4: Shiba E, Watanabe T, Taguchi T, Tsukamoto F, Noguchi S. [Plasma
concentrations of toremifene citrate and N-desmethyltoremifene in postmenopausal
patients with breast cancer--comparison of 120 mg of toremifene citrate
administered once a day and divided into 3 separate doses (t.i.d.)]. Gan To
Kagaku Ryoho. 2000 Feb;27(2):245-9. Japanese. PMID: 10700895.
5: Davies AM, Martin EA, Jones RM, Lim CK, Smith LL, White IN. Peroxidase
activation of tamoxifen and toremifene resulting in DNA damage and covalently
bound protein adducts. Carcinogenesis. 1995 Mar;16(3):539-45. doi:
10.1093/carcin/16.3.539. PMID: 7697811.
6: Okubo T, Nagai F, Ushiyama K, Yokoyama Y, Ozawa S, Kano K, Tomita S, Kubo H,
Kano I. DNA cleavage and 8-hydroxydeoxyguanosine formation caused by tamoxifen
derivatives in vitro. Cancer Lett. 1998 Jan 9;122(1-2):9-15. doi:
10.1016/s0304-3835(97)00359-5. PMID: 9464485.
7: Jones RM, Lim CK. Toremifene metabolism in rat, mouse and human liver
microsomes: identification of alpha-hydroxytoremifene by LC-MS. Biomed
Chromatogr. 2002 Aug;16(5):361-3. doi: 10.1002/bmc.171. PMID: 12210510.
